Novartis drops $2 billion on a phase i allergy drug no one has heard of
Novartis just wrote a cheque that could hit $2 billion for a single molecule that has barely tasted human blood. The Swiss pharma giant is buying Excellergy, a Boston-area outfit whose entire pipeline is one antibody—Exl-111—still crawling through Phase I trials. The kicker: half of the payday is locked to milestones the drug may never meet.
Why a 12-year-old biotech with zero revenue commands biotech unicorn money
Excellergy’s pitch is seductive: an anti-IgE scaffold that supposedly clobbers the allergy pathway faster and deeper than Xolair, the Roche-Novartis cash cow that nets $4 billion a year. The science hinges on a high-affinity, extended-half-life tweak that lets the antibody linger for months, not weeks. If the data survive late-stage fire, Novartis could own the next standard-of-care for food allergies, chronic spontaneous urticaria, even stubborn asthma.
But the deal math is brutal. Up front, Basel wires $1 billion—roughly 25 times Excellergy’s cumulative R&D spend since 2012. The remaining $1 billion is milestone confetti spread across approvals, sales thresholds and pediatric labels. Translation: Novartis pays full biotech exit price for a lottery ticket it can still lose.
Regulators hold the kill switch until 2026
Closing is slated for second-half 2026, contingent on the usual alphabet soup: FTC antitrust nod, EU foreign-direct-investment clearance, and an FDA that has lately grown allergic to mega-deals. If any agency balks, Novartis walks away with nothing but due-diligence bills.
Fiona Marshall, president of Biomedical Research, insists the move “strengthens our allergy portfolio,” yet the portfolio today is essentially Xolair and a clutch of me-too biologics. One success doth not a pipeline make, and Novartis knows it: the company quietly shuttered its Cambridge cell-therapy plant last quarter and pivoted cash to bolt-on buys like this.
Wall Street shrugged. Shares ticked up 0.8 % on the news, a rounding error that screams investor fatigue after a decade of splashy acquisitions that never quite moved EPS. Meanwhile, Roche—still sipping royalties on Xolair—saw its stock dip 1.1 %, the market’s blunt way of asking whether the king of anti-IgE just got dethroned by a pretender with a 40-patient data set.
Lo que nadie cuenta es que Excellergy’s founders already cashed out once: they recycled the same antibody platform from a prior startup sold to Sanofi for $250 million in 2016, watched it die in Phase II, repurchased the IP for pennies, and slapped on a new corporate logo. If lightning strikes twice, Novartis foots the bill; if history repeats, Basel swallows another write-off and allergy patients keep waiting.